ocular hypertension

First in Class Drug for Glaucoma: What Pharmacists Need to Know
First in Class Drug for Glaucoma: What Pharmacists Need to KnowNetarsudil opthalmis solution (Rhopressa, Aerie Pharmaceuticals), is approved by the FDA for treatment of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
How oral and dental hygiene plays a role in glaucomaIn the past couple of years, there has been discussion regarding dental and oral health—specifically the oral biomicrome—as possibly having a relationship to glaucoma.
Novel dual agonist leads to notable IOP loweringThe drug ONO-9054 led to a greater reduction in IOP and a longer duration of reduction in a small clinical trial compared with latanoprost.
Rocket 2 meets safety endpoints for netarsudilNetarsudil ophthalmic solution 0.02% q.d. maintained consistent IOP-lowering efficacy through 12 months for the Rocket 2 trial.
Why 'the more the merrier' doesn't apply to glaucoma monitoringThough ocular hypertension may be the only modifiable risk factor for glaucoma, the second-leading cause of sight loss in the United Kingdom, monitoring for ocular hypertension more than twice a year is not efficient, researchers said.
Cerebrospinal fluid a major player in glaucoma?Imbalance between IOP and cerebrospinal fluid pressure may influence the risk of normal-tension glaucoma or the susceptibility of the optic nerve to ocular hypertension.
Glaucoma therapy: What if a PGA isn’t enough?In this article, Dr Tanna discusses treatment options for glaucoma patients who do not show satisfactory response to a PGA while taking into consideration the two key therapeutic choice factors: IOP-lowering efficacy and tolerability.
High IOP, corneal edema with unknown etiologyA few days ago, a 61-year-old white male presented with a gradual and painless loss of vision in his left eye.
First-in-class glaucoma therapy shows promise in phase II studyTopical AR-13324 0.02% (Rhopressa, Aerie Pharmaceuticals) significantly lowered IOP in eyes with ocular hypertension or open-angle glaucoma in a 28-day phase II study.
Brinzolamide/brimonidine demonstrates broad efficacy in subgroup analysesThe protocols for the pivotal trials establishing the efficacy of the brinzolamide 1%/brimonidine 0.2% fixed combination included pre-planned analyses of subgroups defined by IOP and demographic characteristics.